Seeking Alpha

Valeant Pharmaceuticals (VRX -0.3%) acquires the rights to Visudyne, a treatment for a form of...

Valeant Pharmaceuticals (VRX -0.3%) acquires the rights to Visudyne, a treatment for a form of age-related blindness in which there is an abnormal growth of leaky blood vessels. Valeant pays QLT (QLTI +5.4%) $112.5M upfront for Visudyne, and could pay another $20M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|